Independent
Tenure on this board
5.1 yrs
Also a director at
Aclaris Therapeutics Inc (ACRS)
Meeting calendar
GLUE · Annual meeting · Thursday, June 11, 2026
Monte Rosa Therapeutics Inc
3 nominees · 2 ballot items.
Stockholders will vote to elect three Class II director nominees (Andrew Schiff, Chandra P. Leo, and Anthony Manning) and to ratify the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Market cap
$2.0B
1Y TSR
+310.3%
Board grade
C+
Record date
Apr 16, 2026
Filing
DEF 14A
Meeting concluded · Jun 11, 2026
Follow how the vote landed and what changed on Monte Rosa Therapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Election of Class II Directors
ManagementBoard: FORElect three Class II director nominees (Andrew Schiff, M.D.; Chandra P. Leo, M.D.; and Anthony Manning, Ph.D.) to hold three-year terms expiring in 2029.
- 2
Ratification of Appointment of Independent Registered Public Accounting Firm (Deloitte & Touche LLP
ManagementBoard: FORRatify the audit committee’s appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
5.1 yrs
Independent
Tenure on this board
3.0 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | NEA Management Company, LLC | 9.1% | 7,692,298 | $127M |
| 2 | PRICE T ROWE ASSOCIATES INC /MD/ | 7.8% | 6,606,505 | $109M |
| 3 | TCG Crossover Management, LLC | 5.5% | 4,622,151 | $76M |
| 4 | BVF INC/IL | 5.3% | 4,460,886 | $73M |
| 5 | BAKER BROS. ADVISORS LP | 5.1% | 4,345,736 | $71M |
| 6 | SUVRETTA CAPITAL MANAGEMENT, LLC | 5.0% | 4,226,809 | $70M |
| 7 | Vestal Point Capital, LP | 4.3% | 3,603,465 | $59M |
| 8 | STATE STREET CORP | 4.0% | 3,353,980 | $55M |
| 9 | BRAIDWELL LP | 3.8% | 3,206,574 | $53M |
| 10 | Versant Venture Management, LLC | 3.8% | 3,180,780 | $52M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Monte Rosa Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.6B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.6B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.4B
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$712M
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.5B
Reference
Frequently asked questions
- When is the Monte Rosa Therapeutics Inc 2026 annual meeting?
- Monte Rosa Therapeutics Inc (GLUE) holds its 2026 annual shareholder meeting on Thursday, June 11, 2026.
- What is the record date for the Monte Rosa Therapeutics Inc 2026 meeting?
- The record date for the Monte Rosa Therapeutics Inc 2026 meeting is Thursday, April 16, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Monte Rosa Therapeutics Inc's 2026 meeting?
- The board is presenting 3 director nominees at the Monte Rosa Therapeutics Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Monte Rosa Therapeutics Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Monte Rosa Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.